Pulse Biosciences (NASDAQ:PLSE) Trading Up 6.1% – Here’s What Happened

Pulse Biosciences, Inc. (NASDAQ:PLSE) shares shot up 6.1% during mid-day trading on Friday . The company traded as high as $19.05 and last traded at $18.88. 17,137 shares changed hands during trading, a decline of 76% from the average session volume of 70,556 shares. The stock had previously closed at $17.79.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded Pulse Biosciences to a “sell” rating in a research note on Thursday.

Pulse Biosciences Stock Up 6.9 %

The business’s 50 day moving average is $18.02 and its 200-day moving average is $16.90.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same quarter last year, the company posted ($0.19) earnings per share.

Insider Activity at Pulse Biosciences

In related news, CEO Burke Thomas Barrett sold 50,000 shares of Pulse Biosciences stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $17.42, for a total transaction of $871,000.00. Following the sale, the chief executive officer now directly owns 63,172 shares in the company, valued at $1,100,456.24. The trade was a 44.18 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Robert W. Duggan bought 55,256 shares of the stock in a transaction on Friday, December 13th. The shares were bought at an average cost of $17.18 per share, for a total transaction of $949,298.08. Following the purchase, the director now owns 42,328,717 shares in the company, valued at $727,207,358.06. This trade represents a 0.13 % increase in their position. The disclosure for this purchase can be found here. Insiders own 71.50% of the company’s stock.

Institutional Trading of Pulse Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Quest Partners LLC purchased a new stake in shares of Pulse Biosciences during the second quarter valued at $91,000. Rhumbline Advisers grew its stake in Pulse Biosciences by 6.7% during the 2nd quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock valued at $288,000 after acquiring an additional 1,608 shares in the last quarter. Franklin Resources Inc. acquired a new position in shares of Pulse Biosciences in the 3rd quarter valued at about $378,000. Creative Planning lifted its position in Pulse Biosciences by 113.9% in the 3rd quarter. Creative Planning now owns 21,910 shares of the company’s stock worth $384,000 after buying an additional 11,667 shares in the last quarter. Finally, Barclays PLC boosted its position in Pulse Biosciences by 361.4% during the third quarter. Barclays PLC now owns 30,306 shares of the company’s stock valued at $530,000 after purchasing an additional 23,738 shares during the last quarter. Institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.